Cargando…

Is hemolysis a novel therapeutic target in COVID-19?

Detalles Bibliográficos
Autores principales:	Ousaka, Daiki, Nishibori, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438449/ https://www.ncbi.nlm.nih.gov/pubmed/36059481 http://dx.doi.org/10.3389/fimmu.2022.956671

Ejemplares similares

High Mobility Group Box-1 and Blood–Brain Barrier Disruption
por: Nishibori, Masahiro, et al.
Publicado: (2020)

Understanding of COVID-19 Pathology: Much More Attention to Plasma Proteins
por: Nishibori, Masahiro, et al.
Publicado: (2021)

Complement in Hemolysis- and Thrombosis- Related Diseases
por: Luo, Shanshan, et al.
Publicado: (2020)

Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation
por: Poillerat, Victoria, et al.
Publicado: (2020)

Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis
por: Merle, Nicolas S., et al.
Publicado: (2018)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
por: Wang, Dengli, et al.
Publicado: (2022)

Identification of 3 key genes as novel diagnostic and therapeutic targets for OA and COVID-19
por: Zhang, Yiwei, et al.
Publicado: (2023)

Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis
por: Merle, Nicolas S., et al.
Publicado: (2020)

Three different pathways of IgM-antibody-dependent hemolysis are mainly regulated by complement
por: Bartolmäs, Thilo, et al.
Publicado: (2023)

Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy
por: Eskandarian Boroujeni, Mahdi, et al.
Publicado: (2022)

Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets
por: Hazeldine, Jon, et al.
Publicado: (2021)

GUILLAIN-BARRÉ SYNDROME AND HEMOLYSIS IN COVID-19
por: FERNANDES, MATEUS, et al.
Publicado: (2021)

Acute Hemolysis and Heme Suppress Anti-CD40 Antibody-Induced Necro-Inflammatory Liver Disease
por: Pfefferlé, Marc, et al.
Publicado: (2021)

Novel potential therapeutic targets of alopecia areata
por: Xu, Wen, et al.
Publicado: (2023)

“Hemolysis, or not Hemolysis, that is the Question”. Use of Hydroxychloroquine in a Patient with COVID-19 Infection and G6PD Deficiency
por: Sgherza, Nicola, et al.
Publicado: (2020)

PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19
por: Palma, Giuseppe, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells as a Potential Biomarker and Therapeutic Target in COVID-19
por: Rowlands, Marianna, et al.
Publicado: (2021)

Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
por: Zhu, Manlian, et al.
Publicado: (2022)

Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19
por: Qin, Zhen, et al.
Publicado: (2021)

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics
por: Vallelian, Florence, et al.
Publicado: (2022)

Prognostic value of the hemolysis index in patients with significant hemolysis
por: Cortés, Diego O, et al.
Publicado: (2015)

Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target
por: Ntatsoulis, Konstantinos, et al.
Publicado: (2021)

New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis
por: Nozaki, Yuji
Publicado: (2021)

Editorial: Platelets as Players in Neuropathologies: Novel Diagnostic and Therapeutic Targets
por: Wassmer, Samuel C., et al.
Publicado: (2021)

Tryptophan Catabolism and Inflammation: A Novel Therapeutic Target For Aortic Diseases
por: Ramprasath, Tharmarajan, et al.
Publicado: (2021)

Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
por: Zhai, Yujia, et al.
Publicado: (2021)

Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics
por: Chavda, Vivek P., et al.
Publicado: (2023)

Comprehensive hemocompatibility analysis on the application of diamond-like carbon to ePTFE artificial vascular prosthesis
por: Goyama, Takashi, et al.
Publicado: (2023)

Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19
por: Zhou, Hong, et al.
Publicado: (2022)

Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets
por: Zhou, Xueyin, et al.
Publicado: (2022)

Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics
por: Pal, Soumik, et al.
Publicado: (2022)

Extracellular neutrophil traps: a novel therapeutic target in ANCA-associated vasculitis?
por: Diamantopoulos, Andreas P.
Publicado: (2013)

Park 7: A Novel Therapeutic Target for Macrophages in Sepsis-Induced Immunosuppression
por: Cheng, Yanwei, et al.
Publicado: (2018)

Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
por: McBride, Margaret A., et al.
Publicado: (2021)

Histamine induced high mobility group box-1 release from vascular endothelial cells through H(1) receptor
por: Gao, Shangze, et al.
Publicado: (2022)

SARS-CoV-2 Infection Triggers Phosphorylation: Potential Target for Anti-COVID-19 Therapeutics
por: Chatterjee, Bhaswati, et al.
Publicado: (2022)

Novel aspects of sepsis pathophysiology: NETs, plasma glycoproteins, endotheliopathy and COVID-19
por: Nishibori, M.
Publicado: (2022)

Severe Hemolysis in a COVID-19 Patient with Paroxysmal Nocturnal Hemoglobinuria
por: Otieno, Steve Biko, et al.
Publicado: (2021)

Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets
por: Cortesi, Manuela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q0map0gp958lffhmi6ppjb2li8